Skip to main content

Table 4 Induction treatment regimes

From: Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia

Regime

N (%)

Daunorubicine and Cytarabine (n = 116) or Daunorubicine, cytarabine and mitoxantrone (n = 2)

118 (62.4)

Idarubicine and Cytarabine (n = 26) or Idarubicine, Cytarabine and Etoposide (n = 3)

29 (15.3)

Idarubicine, Cytarabine and Cladribine

20 (10.6)

Mitoxantrone, cytarabine and Etoposide (n = 7) or Mitoxantrone and Cytarabine (n = 2)

9 (4.8)

Daunorubicine, Cytarabine and 6-Thioguanine

8 (4.2)

Other/unknown1

5 (2.6)

  1. 1Including 2 in clinical trial of combination therapy with Tipifarnib, and 1 with Fludarabine, Cytarabine and G-CSF. 2 patients with unknown treatment but known curative intent.